Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-10
2010-02-09
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S400000, C548S565000
Reexamination Certificate
active
07659299
ABSTRACT:
Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.
REFERENCES:
patent: 4783480 (1988-11-01), Wakatsuka et al.
patent: 4895872 (1990-01-01), Nitecki et al.
patent: 6103910 (2000-08-01), Hertel et al.
patent: 6126918 (2000-10-01), Pepys et al.
patent: 6365570 (2002-04-01), Van Kessel et al.
patent: 7045499 (2006-05-01), Pepys
patent: 2006/0122124 (2006-06-01), Pepys
patent: 0915088 (1999-05-01), None
patent: WO 95/05394 (1995-02-01), None
patent: WO 97/46098 (1997-12-01), None
patent: WO 98/50420 (1998-11-01), None
patent: WO 03/013508 (2003-02-01), None
Andersen, O., Vilsgaard Ravn, K.,Sorensen, I.J., Jonson, G., Holm Nielsen, E. and Svehag, S. -E.,Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro.Scand. J. Immunol., 46:331-337, 1997.
Ashton et al., “Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses”,J. Mol. Biol.272, 408-422, 1997.
Askarov et al., “Treatment of osteoarthritis deformans with heparin,”Database biosis 'Online! Biosciences information service67(3), 190-192, 1986.
Athanasou et al., “Localized deposition of amyloid in articular cartilage,”Histopathology(Oxford) 20(1) 41-46, 1992.
Baltz et al., “Calcium-dependent aggregation of human serum amyloid P component”,Biochim. Biophys. Acta701, 229-236, 1982.
Baltz, M.L., de Beer, F.C., Feinstein, A., Munn, E.A., Milstein, C.P., Fletcher, T.C., March, J.F., Taylor, J., Bruton, C., Clamp, J.R., Davies, A.J.S.and Pepys, M.B. Phylogenetic aspects of C-reactive protein and related proteins.Ann. N. Y. Acad. Sci., 389:49-75, 1982.
Baltz, M.L., Dyck, R.F.and Pepys, M.B., Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse.Clin. Exp. Immunol., 59:235-242, 1985.
Bartley, C.J., Orford, C.R.and Gardner, D.L., Amyloid in ageing articular cartilage.J. Pathol., 145:107A, 1985.
Booth et al., “Analysis of autoaggregation and ligand binding sites of serum amyloid P component by in vitro mutagenesis”,Amyloid and Amyloidosis 1998, Ed. By R.A. Kyle and M.A. Gertz, Parthenon Publishing Group, NY, 1998, pp. 23-25.
Booth et al., “Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis”,Nature385, 787-793, 1997.
Borman, “Chemistry Highlights 2002, Medicinal and Combinatorial Chemistry,”Chem. Eng. News80, 37-38, 2002.
Breathnach, S.M., Kofler, H., Sepp, N., Ashworth, J., Woodrow, D., Pepys, M.B. and Hintner, H., Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus.J. Exp. Med., 170:1433-1438, 1989.
Brion, P.H.and Kalunian, K.C.(2003)Osteoarthritis, Oxford Textbook of Medicine, 4th Ed., vol. 3 (Warrell, D.A., Cox, T.M., Firth, J.D.and Benz, E.J., Jr., eds.), Oxford University Press, Oxford, pp. 62-68.
Butler, P.J.G., Tennent, G.A.and Pepys, M.B., Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin.J. Exp. Med., 172:13-18, 1990.
Butler, P.J.G., The folding of chromatin.CRC Crit. Rev. Biochem., 15:57-91, 1983.
Cary, N.R.B., “Clinicopathological importance of deposits of amyloid in the femoral head”J. Clin. Pathol., 38:868-872, 1985.
Caspi, D., Zalzman, S., Baratz, M., Teitelbaum, Z., Yaron, M., Pras, M., Baltz, M.L.and Pepys, M.B. “Imaging of experimental amyloidosis with131I-serum amyloid P component.”Arthritis Rheum., 30:1303-1306, 1987.
Cleaveland et al., “Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program”,Biochem. Pharmacol.49(7), 947-954, 1995.
de Beer, F.C., Baltz, M., Holford, S., Feinstein, A.and Pepys, M.B. Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component.J. Exp. Med., 154:1134-1149, 1981.
de Haas, C.J.C., van Leeuwen, E.M.M., van Bommel, T., Verhoef, J., van Kessel, K.P.M.and van Strijp, J.A.G., Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect. Immun., 68:1753-1759, 2000.
Egan, M.S.,Goldenberg, D.L., Cohen, A.S. and Segal, D., The association of amyloid deposits and osteoarthritis.Arthritis Rheum., 25: 204-208, 1982.
Emsley et al., “Structure of pentameric human serum amyloid P component”,Nature 367, 338-345, 1994.
Goffin, Y.A., Thoua, Y.and Potvliege, P.R., Microdeposition of amyloid in the joints.Ann. Rheum.Dis., 40:27-33, 1981.
Hamazaki et al., Calcium-dependent polymerization of human serum amyloid P component is inhibited by Heparin and dextran sulfate,Biochimica Et Biophysica Acta 998(3), 231-235, 1989.
Hamazaki, H., Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate.J. Biol. Chem., 262:1456-1460, 1987.
Hawkins et al., “Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis”,J. Clin. Invest. 86, 1862-1869, 1990.
Hawkins, P.N., Lavender, J.P.and Pepys, M.B., Evaluation of systemic amyloidosis by scintigraphy with123I-labeled serum amyloid P component.N. Engl. J. Med., 323:508-513, 1990.
Hawkins, P.N., Myers, M.J., Epenetos, A.A., Caspi, D.and Pepys, M.B., Specific localization and imaging of amyloid deposits in vivo using123I-labeled serum amyloid P component.J Exp.Med., 167: 903-913, 1988.
Hawkins, P.N., Tennent, G.A., Woo, P.and Pepys, M.B., Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.Clin.Exp.Immunol., 84:308-316, 1991.
Hind et al., “Binding specificity of serum amyloid P component for the pyruvate acetal of galactose”,J. Exp. Med.159, 1058-1069, 1984.
Hind et al., “Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits”,Lancet, pp. 376-378, Aug. 18, 1984.
Hind, C.R.K., Collins, P.M., Baltz, M.L.and Pepys, M.B. (1985) Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria.Biochem.J.225: 107-111.
Hintner, H., Booker, J., Ashworth, J.,Aubock, J., Pepys, M.B.and Breathnach, S.M., Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro.J. Invest. Dermatol., 91:22-28, 1988.
Hohenester et al., “Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP”,J. Mol. Biol. 269, 570-578, 1997.
Holmgren et al., Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30),Clin. Genet. 40, 242-246, 1991.
Holmgren et al., “Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis”,Lancet, pp. 1113-1116, May 1, 1993.
Hutchinson et al., “Human serum amyloid P component is a single uncomplexed pentamer in whole serum”,Mol. Med.6(6), 482-493, 2000.
Hutchinson et al., “The petraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo”,J. Clin. Invest. 94, 1390-1396, 1994.
International Search Report for PCT/GB 02/03504.
International Search Report for PCT/GB2004/002445.
Iversen, “Amyloid diseases: Small drugs lead the attack,”Nature, 414, 231-233, 2002.
Kelly, “The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease,”Altern. Med. Rev. 3, 27-39, 1998.
Klabunde et al., “Rational design of potent human transthyretin amyloid disease inhibitors”,Nature Struct. Biol.7(4), 312-321, 2000.
Ladefoged, C., Amyloid deposits
Hawkins Philip Nigel
Pepys Mark B.
Frommer & Lawrence & Haug LLP
Kowalski Thomas J.
Li Ruixiang
Lu Deborah L.
Pentraxin Therapeutics Limited
LandOfFree
Compounds inhibiting the binding of sap for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds inhibiting the binding of sap for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds inhibiting the binding of sap for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158567